Your browser doesn't support javascript.
loading
Polio type 2 and 3 eradication: Relevance to the immunity status of individuals living in Germany, 2005-2020.
Kohmer, Niko; Rabenau, Holger F; Rilling, Veronika; Ciesek, Sandra; Enders, Martin; Eggers, Maren.
Afiliação
  • Kohmer N; Institute for Medical Virology, University Hospital, Goethe University Frankfurt am Main, 60596, Frankfurt, Germany. Electronic address: Niko.kohmer@kgu.de.
  • Rabenau HF; Institute for Medical Virology, University Hospital, Goethe University Frankfurt am Main, 60596, Frankfurt, Germany.
  • Rilling V; Laboratory Prof. Gisela Enders MVZ GbR, 70193, Stuttgart, Germany.
  • Ciesek S; Institute for Medical Virology, University Hospital, Goethe University Frankfurt am Main, 60596, Frankfurt, Germany; German Centre for Infection Research, External Partner Site, 60323, Frankfurt, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), 60596, Frankfurt, Germ
  • Enders M; Laboratory Prof. Gisela Enders MVZ GbR, 70193, Stuttgart, Germany.
  • Eggers M; Laboratory Prof. Gisela Enders MVZ GbR, 70193, Stuttgart, Germany.
J Clin Virol ; 164: 105471, 2023 07.
Article em En | MEDLINE | ID: mdl-37130476
ABSTRACT
Since October 2019, poliovirus type 3 (PV3) has been certified as globally eradicated, and further laboratory use of PV3 will be restricted according to the WHO Polio Eradication Initiative and containment measures. To examine a possible gap in PV3 immunity and a lack of immunity against poliovirus type 2 (PV2), which was already declared as eradicated in 2015, neutralising antibodies against polioviruses (PV) of individuals living in Germany (n = 91,530 samples; mainly outpatients (≈90%) who received immune status testing) were investigated from 2005 to 2020 (age distribution <18 years 15.8%, 18-64 years 71.2% and ≥65 years 9.5% for 2005-2015; <18 years 19.6%, 18-64 years 67% and ≥65 years 11.5% for 2016-2020). The results showed that the proportion of sera exclusively lacking antibodies against PV3 was 10.6% in 2005-2015 and 9.6% in 2016-2020 and against PV2 2.8% in 2005-2015. As there is decreased protection against PV3 and to detect potential antigenically (immune escape) variant PVs not covered by used vaccines, we recommend continued testing of PV1 and PV3.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Poliomielite / Poliovirus Limite: Adolescent / Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Poliomielite / Poliovirus Limite: Adolescent / Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article